Open this publication in new window or tab >>Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands.
Precision Medicine – Biological Resource Center and Department of Transfusion Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, CA, USA.
Section of Genetics and Genomics, Department of Metabolism, Digestion, and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Disciplinary Domain of Science and Technology, Mathematics and Computer Science, Department of Information Technology, Division Vi3.
Uppsala University, Science for Life Laboratory, SciLifeLab.
Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy; Clinical Medicine and Hepatology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands.
Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
Section of Genetics and Genomics, Department of Metabolism, Digestion, and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy; Precision Medicine – Biological Resource Center and Department of Transfusion Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
Uppsala University, Science for Life Laboratory, SciLifeLab.
Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden; Clinical Nutrition Unit, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Medicine (H7), Karolinska Institute, Huddinge, Sweden; Department of Endocrinology, Karolinska University Hospital, Huddinge, Sweden.
Show others...
2025 (English)In: Clinical and Molecular Hepatology, ISSN 2287-2728, E-ISSN 2287-285X, Vol. 31, no 4, p. 1252-1268Article in journal (Refereed) Published
Abstract [en]
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) may progress to liver inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. So far, genome-wide association studies explain a small fraction of MASLD heritability.
Methods: We sought to identify novel genetic determinants of MASLD by exploring interactions between genetic variants and body mass index (BMI). First, we examined genome-wide interactions with BMI for circulating alanine aminotransferase (ALT) levels using UK Biobank data. For identified loci, we next examined associations with hepatic proton density fat fraction (PDFF) in 35,146 independent UK Biobank participants. Associations with PDFF were replicated in four independent European cohorts, followed by a phenome-wide association study. Finally, we used human liver epigenomic maps and CRISPR/Cas9 experiments in vitro and in vivo to functionally characterize the CYP7A1 locus.
Results: Thirteen loci interact with BMI for ALT (P<5E-8), including eight well-known genetic modulators of MASLD. Two loci-UBXN2B/CYP7A1 and GIPR-are additionally associated with PDFF. For the intronic rs34783010 in GIPR, the minor T allele is associated with lower BMI and higher HbA1c and liver triglyceride content in humans. The UBXN2B/CYP7A1 locus is associated with PDFF in four additional European cohorts. Epigenomic data and in vitro experiments in human liver cells prioritise rs10504255 and CYP7A1 as the functional effectors in this locus. Perturbation of CYP7A1 orthologues using CRISPR/Cas 9 results in less liver fat in 10-day-old, metabolically challenged zebrafish larvae.
Conclusions: A genome-wide single nucleotide polymorphismxBMI design fuelled identification of two MASLD genes: CYP7A1 and GIPR.
Place, publisher, year, edition, pages
The Korean Association for the Study of the Liver, 2025
Keywords
Gene-environment interaction, Genome-wide association study, MASLD, Gastric inhibitory polypeptide receptor, CYP7A1
National Category
Medical Genetics and Genomics Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-572322 (URN)10.3350/cmh.2025.0159 (DOI)001619038300001 ()40452229 (PubMedID)2-s2.0-105021534396 (Scopus ID)
Funder
EU, Horizon 2020Knut and Alice Wallenberg FoundationSwedish Heart Lung FoundationSwedish Research CouncilEU, Horizon 2020Swedish Cancer Society
2025-12-112025-12-112026-06-25Bibliographically approved